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A B S T R A C T
Crk (C10 regulator of kinase) adaptor proteins are highly expressed in many types of human cancers and often
contribute to aggressive cancer phenotypes. Crk II, a member of CRK family, has been reported to regulate cell
migration and metastasis in breast cancer cells. However, its role in other cancer types has not been reported. In
this study, we investigated the molecular function of Crk II in prostate cancer (PCa) cells (CWR-22rv1) in vitro
and using a mouse tumor model. Results showed that Crk II knockdown by shRNA-mediated silencing (Crk II-
shRNA) in the PCa cells signiﬁcantly inhibited both cancer cell migration and invasion in cell culture study. Crk
II-shRNA cancer cells also signiﬁcantly decreased colony formation in vitro, but had no signiﬁcant reduction of
tumor volume after 4 weeks of cancer cell xenografting in vivo when compared to the scramble control.
Interestingly, Crk II-shRNA cancer cells showed a greatly reduced level of insulin-like growth factor 1 receptor
(IGF-1R) and decreased signaling of the IGF-1R/PI3K/Akt axis upon IGF-1 ligand stimulation. A close
interaction between Crk II and IGF-1R was demonstrated upon co-immunoprecipitation of IGF-1R with Crk II
protein. Further, treatment of cells with either proteosomal degradation or protein synthesis inhibitor showed
higher proportion of ubiquitin-associated IGF-1R and faster degradation of IGF-1R in Crk II-shRNA cells in
comparison with that in the control cancer cells. Taken together, these data suggest that Crk II plays an
important role in the regulation of IGF-1R protein stability and aﬀects downstream of IGF-1R signaling
pathways. Therefore, targeting Crk-II can block IGF-1R growth signaling and suppress cancer cell invasion and
progression.
1. Introduction
Prostate cancer (PCa) is the most common type of cancer in men
and metastasis of treatment resistant cancer is a major cause of
mortality [1,2]. Thus, it is crucial to understand the molecular
mechanisms involved in cancer cell motility and invasion that lead to
PCa metastasis. It has been reported that the IGF-IR signaling plays a
critical role in PCa progression and tumorigenesis [3,4]. IGF-IR is a
member of the type 1 family tyrosine kinase receptors and both IGF-1
and IGF-2 serve as IGF-1R ligands [3,5]. Circulating IGF-1 levels
showed positive correlation with disease progression of PCa, and high
IGF-IR expression and activation were associated with both primary
and metastatic PCa [4,6]. Several IGF-IR targeting monoclonal anti-
bodies are being evaluated in the clinic [7–9].
Crk (C10 regulator of kinase) belongs to the group of Src homology-
2 (SH2) adaptor proteins and contains both SH2 and SH3 domains.
Crk adaptor proteins bind to the phospho-tyrosine motifs of receptor
tyrosine kinases (RTKs) and relay extracellular signals to intracellular
pathways. Crk proteins have been well documented for overexpression
in various cancers including PCa [10–14]. Crk II, a member of Crk
adaptor proteins, has been reported to promote migration and invasion
of breast cancer cells and induce anchorage-independent growth [15–
17]. A study also showed that IGF-IR can interact with Crk II and
induce downstream signaling through Crk II phosphorylation at
tyrosine-221 in NIH-3T3 overexpressing IGF-IR cells [18]. However,
little is known about the mechanisms of Crk II interaction with IGF-IR
in cancer cells.
In this study, we investigated the eﬀects of Crk II on cell migration,
invasion and colony formation in vitro using a stable Crk knockdown
(k/d) PCa cell line (CWR-22rv1) in comparison with cells transfected
with scrambled control shRNA. The results demonstrated that Crk II k/
d inhibited PCa cell motility and growth, and directly impacted IGF-IR
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protein stability and signaling by modulating ubiquitination and
degradation pathway of IGF-IR.
2. Materials and methods
2.1. Cell Culture and antibodies used for detection
CWR-22Rv1 PCa cell line was obtained from ATCC (American Type
Culture Collection) (Manassas, USA). Cells were cultured in a humidi-
ﬁed CO2 incubator, 37 °C, in RPMI medium supplemented with 10%
FBS (Hyclone) and 100 U/ml Penicillin/ Streptomycin from Sigma-
Aldrich (St. Louis, MO, USA) as we reported before [19]. Antibodies for
Western blotting of Crk II, IGFR-1β, phospho-Akt-473, Akt, phospho-
Erk 44/42 and Erk 44/42 were purchased from Epitomics and other
detection antibodies including phospho-IGFR-(1135/1136), p-4EBP1,
p-mTOR, m-TOR, S6 kinase were from Cell signaling. Secondary
detection antibodies were from Santa Cruz Biotechnology or other
indicated sources.
2.2. Construction of shRNA knockdown cells
Lentiviral pLKO.1 shRNA from Open Biosystems was used for
construction of a stable shRNA-Crk II knockdown cancer cell lines.
Three shRNA sequences were used to establish the Crk II knockdown
cell lines: shRNA 1 (TRCN0000021847): TTGTCCCGGATTCTCAAGATG;
shRNA 2 (TRCN0000021844) TTAAAGTCAAAGAGGGCTCGC; and
shRNA 3 (TRCN0000021848): TTCCCATTAAAGTCAAAGAGG.
Scrambled shRNA in pLKO.1 vector was used as a control. Viral
packaging and cancer cell transfection were performed according to the
manufacturer's instructions where the stable Crk II knockdown or control
cells were selected and maintained in RPMI medium containing 1 µg/ml
puromycin as previously reported [20].
2.3. Quantitative polymerase chain reaction (qPCR)
RNA was extracted using Trizol (Thermo Fischer Scientiﬁc) and
total RNA was used for cDNA synthesis using SuperScript™ III First-
Strand Synthesis kit (Invitrogen) as described before [19]. Using SYBR
green dye, qPCR was conducted using CFX96 Touch™ real-time PCR
detection system (Bio-Rad Laboratories). Crk II mRNA expression was
quantiﬁed with GAPDH as a control using 2-ΔΔCt method [20].
2.4. Migration and invasion assays
Migration assays were conducted as described previously [21].
Brieﬂy, cells were seeded in serum-free culture medium in a transwell
plate (6 wells, 8 µm pore) (Corning, NY) and the lower chamber
containing complete medium. Cell migration was determined after
48 h of culturing the cells at 37 °C. Similarly, for the invasion
experiments, cells were plated in the transwells with precoated matrigel
(BD Biosciences) in 0.01 M Tris (pH 8.0) and 0.7% NaCl solution. After
48 h in culture, cells on the upper side of the membrane were removed
with the cotton swab and the cells on the lower surface were stained
using 0.5% crystal violet. Images were captured using a phase-contrast
microscope and ﬁve images were taken per well and replicate wells
(n=3) were included in each experiment. The assays were repeated 2
times. Quantiﬁcation of the number of migratory cells per image was
performed using image J software.
2.5. Colony formation assays
Cancer cells (1000 or 100 per well) were seeded in 6 well plates,
cultured for two weeks in a humidiﬁed incubator at 37 °C and 5% CO2,
and culture medium was refreshed every 3–4 days during the experi-
ment. Cells were ﬁxed with 4% paraformaldehyde, stained using 0.01%
crystal violet solution overnight and washed with PBS as reported
before [20]. Colonies were imaged and counted with triplicates. Growth
inhibition was computed as a percentage of the scrambled control.
2.6. In vivo xenograft studies
The animal study protocol was approved by the Animal Welfare
Committee at The University of Texas Medical School at Houston and
the studies were conducted in accordance with the guidelines of animal
care as described before [22]. Athymic nu/ numale mice (Charles River
Laboratories) were used for in vivo tumor growth study with Crk II-
shRNA PCa cells in comparison with the scrambled control cells.
Procedures for tumor implantation and monitoring of tumor growth
were as reported previously [22]. Brieﬂy, cancer cells (5×106/ mouse)
were implanted subcutaneously into mice at 7 weeks of age and tumor
size was monitored weekly using an electronic caliper. The tumor
volume was calculated using a formula: tumor volume (mm3)
=(width)2xlength/2. Tumor tissues were harvested at the end of study
by snap freezing in liquid nitrogen for ex vivo analysis of CRK-II and its
related signaling molecules.
2.7. Western blotting (WB)
Cancer cells were cultured to 70–80% conﬂuency in normal culture
conditions before the analysis. For IGF stimulation study, cells were
cultured in a low serum (1% FBS) overnight, then treated with IGF-1
(10 ng/ml) for diﬀerent time periods. Cell lysates were prepared by
adding lysing the cells in RIPA buﬀer (Calbiochem) containing protease
and phosphatase inhibitor cocktail. The protein concentration was
determined using Bio-Rad protein assay reagents based on the
manufacturer's instruction and 30–50 µg of protein lysates was used
for SDS-PAGE gel separation and WB was conducted as described
previously [20]. WB detection was performed with an enhanced
chemiluminescence kit (Denville Scientiﬁc), imaged using a
FluorChem M imager and quantiﬁed based on the staining density by
Image J software.
2.8. Co-immunoprecipitation (co-IP)
Cell lysates were incubated overnight with 1.5 µg of Crk II or 2.5 µg
of IGF-IRβ antibody (Epitomics) and Dynabeads® protein G (Novex
Biotechnologies) were subsequently added for 4 h at 4 οC with slow
mixing. The supernatant was removed using a magnetic separator and
the magnetic beads were washed with the sample buﬀer. 2X SDS
Laemmli sample buﬀer (Biorad) with β-mercaptoethanol was added to
the beads, heated at 80 οC for 8 min and then subjected to WB for
detection of IGF-IR and Crk II [20].
2.9. Proteosomal inhibitor treatment and ubiquitination assays
Cells were treated with 10 µm of MG-132 (EMD Millipore, MA,
USA) for 4 h in culture before lysate preparation. For detection of
ubiquitination of IGF-IR, pull-down using IGF-IR antibody and WB
using anti-ubiquitin PD-4 antibody (Cell Signaling Technology) was
performed to detect ubiquitination as described previously [20].
2.10. Cycloheximide treatment
Cells were seeded in a 6-well culture plate a day before and
cycloheximide (EMD Millipore, MA, USA) at 100 µg/ml was added
into the culture for various time periods. Cell lysates were collected at
0, 8, 12 and 24 h after the cycloheximide treatment and evaluated for
IGF-IR by WB [20].
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3. Results
3.1. Crk II knockdown inhibited cancer CWR-22rv1 cell migration
and invasion
In order to examine the functional role of Crk II in PCa, we
abrogated Crk II expression in CWR-22rv1 (an androgen-independent
PCa cell line), and established stable Crk II knockdown cells (Crk II-
shRNA) using a lentiviral vector system. In comparison with the vehicle
control cells (Scramble-shRNA), the Crk II-shRNA cells had low to no
detectable levels of CRK II by western blotting (Fig. 1 A). Quantitative
analysis using q-PCR showed a signiﬁcant decrease of Crk II RNA
transcripts in all three Crk-II shRNA knockdown cell lines in compar-
ison with that of the scramble control cells (Fig. 1 B). In order to
compare the eﬀects of Crk II knockdown on cancer cell migration and
invasion, we determined both cell migration and invasion of Crk II-
shRNA cells in comparison with the scramble control cells using
transwell assays. Crk II-shRNA cells exhibited signiﬁcantly lower
motility than that in the scrambled control cells (p < 0.05) (Fig. 1 C).
Crk II-shRNA cancer cells also showed a signiﬁcant decrease of
invasiveness in comparison with the Scrambled- control (p < 0.05);
(Fig. 1 D). As all three shRNA cell lines showed similar results, the data
from the shRNA 2 knockdown cell line is shown in Fig. 1 C and D.
Therefore, following studies were carried out using the shRNA 2
knockdown cancer cells.
3.2. Crk II knockdown suppressed colony formation in vitro but did
not signiﬁcantly inhibit tumor volume in vivo
To investigate the role of Crk II in CWR22rv1 cell proliferation, we
Fig. 1. Crk II knockdown inhibited CWR22rv1 cancer cell migration and invasion. (A) Western blot detection of Crk II protein levels in Crk-II-shRNA cells; (B) qRT-PCR detection of
Crk II mRNA in Scrambled and Crk II-shRNA cells; (C) Representative images and quantiﬁcation of average numbers of cells detected in migration using a transwell assay, n=3; (D)
Representative images and quantiﬁcation of cells invading through a matrigel-coated membrane insert after 48 h cell culture. Experiments were repeated three times (n=3), and *
indicates p value < 0.05. The data in C &D show the results from the shRNA 2 stable cancer cell line. The original images were 1360 pixels*1024 pixels at 72 dpi, (length of 18’’ *14’’) and
a portion of the image (4’’ *4’’) from the original 72 dpi image (288 pixels *288 pixels) is shown. The resolution of the images was adjusted from 72 to 300 dpi using Adobe photoshop
program. For the bar graph, 10 separate images were taken from 3 experimental replications and the error bars represent the standard deviation (sd) calculated from the representative
images.
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performed colony formation assays using cell culture study. Crk II-
shRNA cells showed both reduced numbers and the size of colonies in
comparison with that in the scramble control cells (Fig. 2 A). Number
of colonies formed from a ﬁxed number of seeding cells (both 100 and
1000 cells/ well) decreased by 40% in Crk II knockdown cells as
compared to that in control cells (Fig. 2 B). Crk II-shRNA cells also had
slightly smaller tumors as compared to the scrambled-shRNA control
after 4 weeks post implantation of cancer cells in vivo, even though the
diﬀerences in the tumor volume were not statistically signiﬁcant (Fig. 2
C). The smaller impact on tumor growth in vivo than that in the cell
culture study may be caused by the diﬀerences of assay sensitivity and
physiological conditions in in vivo and in vitro studies. Ex vivo assay of
tumor lysates showed that Crk II and p-Akt levels were signiﬁcantly
decreased and IGF-IR was reduced in Crk II shRNA tumors in
comparison with that in the scrambled control tumors (Fig. 2 D).
3.3. Crk II knockdown downregulated IGF-IR levels and suppressed
PI3K/Akt signaling pathway in CWR-22rv1 cells
To understand the Crk II-mediated signaling pathways that are
crucial in the cell migration and invasion, we compared expression
levels of a panel of RTKs including IGF-1R and epidermal growth
factor receptor (EGFR) family receptors in the Crk II-shRNA and
scramble-shRNA cells. Results showed that IGF-IR expression was
signiﬁcantly reduced and its downstream key signaling molecules such
as p-Akt, p-mTOR, p70S6K and p4EBP1 were also impacted as
determined by WB (Fig. 3 A). The right bar graph in Fig. 3. A shows
quantiﬁcation of the WB staining intensity. But the levels of EGFR
family members showed no changes (Suppl. Fig. S1). To determine if
Crk II interacts directly with IGF-IR as an adaptor protein, we
conducted co-ip using IGF-IR and Crk II antibodies and WB detection.
The results revealed that IGF-IR was directly associated with Crk II
(Fig. 3 B). Further, we determined IGF-IR levels and its downstream
signaling proteins in Crk II-shRNA cells in comparison with that in the
scramble control upon IGF-1 stimulation. As expected, p-IGF-IR-
1135/1136, p-Akt-473, p-mTOR, p70S6K and p4EBP1 levels de-
creased in Crk II-shRNA cells when compared with Scrambled-control
cells in the presence of IGF-1 for 15 30 and 60 min (Fig. 3 C). At
30 min, IGF-1-induction of p-IGF-IR-1135/1136 is maximum, after
which it reduces at 60 minThese results indicate that Crk II can
modulate the levels of IGF-IR and impact IGF-IR downstream signal-
ing through PI3K/ Akt in PCa cells.
3.4. Crk II knockdown increased ubiquitination and degradation of
IGF-IR
To investigate the mechanism of IGF-IR downregulation by Crk II,
we determined the eﬀects of Crk II on IGF-IR degradation pathway.
Fig. 2. Crk II knockdown inhibited colony formation in vitro but had less signiﬁcant eﬀects on tumor growth in vivo. (A) Representative images of colony formation by Crk II
knockdown cells in comparison with the scramble control cancer cells; (B) Reduced numbers of colonies formed by Crk II-shRNA cancer cells in comparison with the that by the
scrambled control cells. The cancer cells (seeding density at 1000 cells/well) were cultured for 10 days at 37 °C cell culture incubator and medium were refreshed every 3 days; (C)
Tumor volumes of Crk II knockdown cells (Crk II-shRNA) were not signiﬁcantly aﬀected in comparison with that in the Scrambled-shRNA control cells n=3. (D) WB detection of Crk II
in ex vivo tumor lysates.
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Results showed that IGF-IR levels were increased in Crk II-shRNA cells
after treatment with a proteosomal inhibitor (MG132, at 10 µm) (Fig. 4
A), suggesting that the eﬀect of Crk II on IGF-IR levels involves post-
translational regulation through proteosomal degradation pathway. As
ubiquitination of IGF-1R is important for protein proteosomal degra-
dation, we further investigated IGF-IR ubiquitination in Crk II knock-
down cells. Our results demonstrated that ubiquitinated IGF-IR
increased in Crk II knockdown cells in comparison with that in
scrambled controls when the comparable levels of IGF-IR were used
for the detection (Fig. 4 B). We also determined the eﬀect of Crk II
knockdown on IGF-IR by treatment with cycloheximide, an inhibitor of
protein synthesis. Results showed that IGF-IR levels were declined
faster in the Crk II knockdown cancer cells (close to 50% of IGFR-IR
remaining) in comparison with that in the control cells (80% IGFR-IR
remaining) after 24 h in the presence of cycloheximide (Fig. 4 C and D).
These data indicate that Crk II regulates IGF-IR at the post-transla-
tional level by stabilizing IGF-IR and preventing it from ubiquitination
and degradation.
4. Discussion
In this study, we revealed an important role of Crk II as an adaptor
protein of IGF-IR in invasion and migration of androgen-independent
PCa cells. Crk family proteins are one of the crucial regulators in the
signaling of many RTKs [10,15,17,23]. Crk II overexpression in breast
and lung cancer patients is shown to be correlated with the adverse
tumor grade [12,13]. In this study, we demonstrated for the ﬁrst time
that Crk II plays an important role in migration and invasion of
CWR22Rv1 prostate cancer cells. The results are consistent with the
reported roles of Crk II in breast and lung cancer cells [14].
It has been reported that IGF-IR signaling is important for PCa
progression and development [3]. Up-regulated IGFR mRNA and
Fig. 3. Crk II knockdown decreased levels of IGF-1R and its downstream signaling in CWR22rv1 cancer cells. (A) WB detection (30 μg protein loaded in each well) of IGF-1R (antibody
against IGF-1R β subunit) and the downstream signaling molecules of PI3K-Akt pathway. Bar graph shows the quantiﬁcation of the staining intensities of each protein using the software
of the FluorChem M imager (ProteinSimple); (B) Interaction of Crk II and IGF-1R by co-immunoprecipitation (i.p.). The CWR22rv1 cancer cell lysates were used to conduct pull down
with either anti-Crk II antibody or anti-IGF-1Rβ antibody and isotype IgG (IgG) was used as a control; (C) Eﬀects of IGF 1 stimulation on IGF-1R signaling in Crk II-shRNA knockdown
cancer cells in comparison with the scramble control. WB detection was conducted similarly as in (A). Cancer cells were cultured in a low serum medium (1% FBS) over night and
stimulated with IGF (10 ng/ml) for diﬀerent times (15 and 30 min).
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protein levels have been noted in both primary PCa and patients with
bone metastases [6]. Increased IGF-IR expression and signaling were
reported in vitro and in vivo xenografts in androgen-independent
LNCaP/ C4-2 cells [24,25]. Previous studies have shown that IGF-IR
signaling was aﬀected by Crk II association with IRS-4, a downstream
IGF-IR signaling molecule [18,26]. In this study, we demonstrated that
Crk II modulated IGF-IR levels by direct association of the two
proteins. We also revealed that IGF-IR was modulated by Crk II
through ubiquitination and proteosome-mediated IGF-IR degradation
in PCa cells.
Crk II has a role in PI3-K activation and signaling through AKT/
mTOR pathway [27,28] [29]. A previous study has shown that IGF-1
promoted migration of androgen-independent PCa cells through PI-
3K-Akt signaling [30]. An mTOR inhibitor study revealed that mTOR
regulated invasion gene signatures in PCa cells through 4EBP1 path-
way [31]. This study using CWR22rv1 cells demonstrated an important
role of Crk II in migration and invasion and a close link between Crk II
and IGF-IR/ pAkt-mTOR signaling.
Earlier studies have shown an interaction of Crk II with IGF-IR
phosphotyrosine residues in IGF-IR-overexpressing NIH-3T3 cells
[18,26]. The co-immunoprecipitation data conﬁrmed the interaction
of Crk II and IGF-IR in PCa cells. Both Grb10 and β-Arrestin were
reported as adaptor proteins for IGFR ubiquitination [32]. This study
indicated that CRK II also was involved in modulation of IGF-IR levels
and stability at post-translational level.
In summary, this study demonstrated an important role of Crk II in
IGF-IR regulation in androgen-independent PCa cells. The data suggest
that Crk II/ IGF-IR signaling axis can promote colony formation,
migration and invasion in PCa cells. Thus, targeting Crk II/ IGF-IR axis
may oﬀer a valuable therapeutic strategy for treatment of androgen-
independent metastatic prostate cancer.
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